Canadian regulator okays Natco's Ondansetron

Hyderabad-based pharmaceutical company, Natco Pharma, has received an approval from the Canadian regulatory Agency (TPD - Health Canada) for its product - Ondansetron 4 mg and 8 mg tablets.

According to a release issued by Natco to the BSE today, the approval has been accorded to Natco's marketing partner, IP Generics of Canada, which will facilitate Natco to market its products in Canada.

TPD - Health Canada had already approved the Citalopram Hydrobromide 20 mg and 40 mg tablets of Natco, the release added.